PARSIPPANY, N.J., Feb. 3, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Pacira. The shares are expected to begin trading on the NASDAQ Global Market under the symbol "PCRX" on February 3, 2011. In addition, Pacira has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares to cover over-allotments, if any.
Barclays Capital Inc. and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Wedbush PacGrow Life Sciences and Brean Murray, Carret & Co. are acting as co-managers for the offering.
The offering of these securities will be made only by means of a prospectus, copies of which may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717, or by calling 1-888-603-5847 or by emailing Barclaysprospectus@broadridge.com; or from Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, by calling 1-800-747-3924.
A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission.
About PaciraPacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, commercialization and manufacture of novel pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers. The company's most advanced product candidate, EXPAREL™, a bupivacaine-based product, has completed Phase 3 clinical development for postopera